Central nervous system tolerance to boron neutron capture therapy with p-boronophenylalanine. by Morris, G. M. et al.
British Joumal ofCancer (1997) 76(12), 1623-1629
© 1997 Cancer Research Campaign
Central nervous system tolerance to boron neutron
capture therapy with p-boronophenylalanine
GM Morris1, JA Coderre2, PL Micca2, CD Fisher2, J Capala and JW Hopewell1
'Research Institute, University of Oxford, Churchill Hospital, Oxford OX3 7L, UK; 2Medical Department, Brookhaven National Laboratory, Upton, NY 11973, USA
Summary A rat spinal cord model was used to evaluate the effects of boron neutron capture irradiation on the central nervous system (CNS),
using a range of doses of the boron delivery agent pboronophenylalanine (BPA). Three doses of BPA 700, 1000 and 1600 mg kg-' were used
to establish the biodistribution of boron-10 ('°B) in blood, spinal cord and brain over a 3-h period after intraperitoneal (ip) administration. Atthe
lowest dose of BPA used, blood '°B levels remained relatively stable over the 3-h sampling period. With the two higher doses of BPA, blood
'°B concentrations were greatest at 1 h after BPA administration, and thereafter exhibited a biphasic clearance profile. The largest decline in
blood '°B levels occurred between 1 and 2 h after ip injection and was most pronounced (approximately 45%) in the highest BPA dose group.
Considered overall, '°B concentrations were marginally lower in the spinal cord than in the brain. Levels of 10B in both of these organs showed
a slow but progressive increase with time after administration of BPA. The '°B concentration ratio for blood relative to CNS tissue increased
with BPA dosage and reached a peakvalue of approximately 10:1 in the highest BPA dose group, at 1 h after ip injection. However, at 3 h after
injection the 10B concentration ratios had decreased to approximately 3:1 in all ofthe BPA dose groups. After irradiation with thermal neutrons
in combination with BPA at blood '°B concentrations of approximately 42 and approximately 93gig g-1, myelopathy developed after latent
intervals of 20.0 ± 0.6 and 20.0 ± 1.2 weeks respectively. ED50 values (+ s.e.) for the incidence of myelopathy were calculated from probit-
fitted curves, and were 17.5 ± 0.7 and 25.0 ± 0.6 Gy after irradiation with thermal neutrons at blood '°B levels of approximately 42
and approximately 93,g g-1 respectively. The compound biological effectiveness (CBE) factor values, estimated from these data, were
0.67 ± 0.23 and 0.48 ± 0.18 respectively. This compared with a previous estimate of 0.88 ± 0.14 at a blood '°B concentration of approximately
19gg g-'. It was concluded that the value of the CBE factor was not influenced by the level of '°B in the blood, but by the blood:CNS
'°B concentration ratio. In effect, the CBE factor decreases as the concentration ratio increases. Simulations using boron neutron capture
therapy (BNCT) treatment planning software indicate a significant therapeutic advantage could be obtained in moving to higher BPA doses
than those in current clinical use.
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Primary brain tumours are relatively common, with an annual inci-
dence of about 10 per 100 000 of the population. Neuroepithelial
tumours, gliomas, constitute approximately half of all primary
brain tumours. Patients with the most malignant gliomas (grade
IV) usually die within a year of diagnosis (Bloom, 1982). Many
high-grade gliomas are inoperable and do not respond to conven-
tional therapies, which include radiotherapy and/or chemotherapy
(Leibel and Sheline, 1987; Leibel et al, 1994). Newer treatment
modalities, including hypoxic cell sensitizers or fast neutrons,
have also proved ineffective (Gutin, 1992). Gliomas are not
known to metastasize via the blood stream and are only occasion-
ally dispersed along cerebral spinal fluid pathways. Therefore, any
treatment capable of sterilizing the primary tumour locally will
result in a high probability of 'cure'. Boron neutron capture
therapy (BNCT) offers the potential for achieving this objective.
BNCT is a bimodal approach to cancer therapy. Boron-10
('0B)-enriched compounds are used to deliver '°B to tumours.
Once tumour uptake of a given boron delivery agent has been
maximized, relative to the surrounding normal tissues and blood,
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irradiation with low-energy neutrons (thermal/epithermal
neutrons) takes place. Thermal neutrons, or epithermal neutrons,
which become thermalized at depth in tissue, are captured by 10B
atoms, with the resultant fission reaction producing a-particles
and lithium-7 (7Li) ions. These particles have a limited range of
<9 ,um in tissue. Thus, in theory, it is possible to selectively
irradiate a tumour with high linear energy transferase (LET)
radiation, while sparing the adjacent normal tissues.
The response of a limited number of patients with brain
tumours, treated in Japan using a thermal neutron beam, after the
administration of the boron delivery agent borocaptate sodium
(BSH), has indicated that BNCT is of potential clinical value
(Hatanaka et al, 1991). During late 1994, a new clinical study
involving the treatment ofglioblastoma (grade IV) was initiated at
Brookhaven National Laboratory (BNL) in the USA. An alterna-
tive boron delivery agent, p-boronophenylalanine (BPA) is being
used together with a more deeply penetrating epithermal neutron
beam (Coderre et al, 1997).
In previous reports (Morris et al, 1994a; Coderre et al, 1995),
the effects of BNC irradiation on the spinal cord of Fischer 344
rats was assessed at '°B concentrations ofapproximately 12 ,ug g-'
and approximately 19 ,ug g-', using BPA as the delivery agent, and
the compound biological effectiveness (CBE) factors were similar.
Blood '°B levels measured in patients involved in the BNL clinical
study are similar to those that were used in the rat (Coderre et al,
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Table 1 Thermal beam exposure times, blood 10B content at the time of irradiation and physical absorbed doses for the
two BPA treatment groups
Thermal beam Blood '°B Thermal beam 1OB(n, a)7Li Total
exposure time content dose component dose component dose
(MW min) (,ug g-1) (Gy) (Gy) (Gy)
12.0 39.1 ± 1.0 3.6 9.2 12.8
13.0 43.6 ± 2.2 3.9 11.2 15.1
15.0 41.6 ± 1.0 4.5 12.3 16.8
17.0 44.6 ± 1.6 5.1 14.9 20.0
10.0 92.4 ± 2.3 3.0 18.2 21.2
12.0 95.6 ± 1.4 3.6 22.6 26.2
13.0 90.7 ± 1.7 3.9 23.2 27.1
1997). However, it is now proposed to increase the dose of BPA
administered to patients in the BNL study, and as a consequence,
the '°B concentration in the blood at the time of irradiation. It is
also intended to evaluate new BPA administration protocols.
To evaluate the potential effects of different '°B biodistribution
profiles on the CBE factor for BPA, an additional series of rat
spinal cord irradiations were carried out. Irradiations with thermal
neutrons using a BPA administration protocol, which resulted in
considerably higherblood:CNS '0B concentration ratios than those
previously obtained using BPA. The findings of this study are
reported below.
MATERIALS AND METHODS
Studies were carried out using young adult (12-week-old) male
Fisher 344 rats, weighing 260-290 g. They were housed, two to a
cage, in temperature-controlled rooms and had access to food and
water ad libitum. Rats were maintained in a controlled light/dark
cycle, with lights on between 07.00 and 19.00 h.
p-Boronophenylalanine (BPA) containing 4.9% '0B (Boron
Biologicals, Raleigh, NC, USA) was used as the boron delivery
agent. The BPA was dissolved in a fructose solution, as described
previously (Coderre et al, 1994), and administered by intra-
peritoneal (i.p.) injection.
Dosimetry
Rats were irradiated using the thermal beam at the Brookhaven
Medical Research Reactor (BMRR), a 3-MW water-moderated
nuclear reactor. The dosimetry of the mixed radiation field, which
consisted mainly ofthermal neutrons, fast neutrons, gamma rays and
charged particles (a, 7Li, 'H, 14C) from the '0B(n, a)7Li and '4N(n,p)-
'4C reactions, were calculated using thermal neutron fluence data
from bare and cadmium-covered gold foils and wires (inserted into
the spinal cords ofdead rats and aplastic phantom). Auniform distri-
bution of2.6% w/w nitrogen in tissue was assumed. Measurement of
the gamma dose was made by inserting thermoluminescent dosime-
ters (TLD-700: Harshaw Chemical, Solon, OH, USA) into the spinal
canal of dead rats. The combined fast (> 10keV) neutron and
gamma doses at the beam port were measured using paired tissue-
equivalent (TE) plastic ionization chambers containing TE gas
(Rossi gas), and a graphite chamber filled with carbon dioxide gas.
The fast neutron dose rate was calculated by subtraction of the
gamma dose rate from the total dose rate. Monte Carlo computation,
normalized to the in-air neutron dosimetry, was used to estimate the
fast neutron dose rate at the level ofthe spinal cord.
The thermal neutron fluence in the spinal canal was
3.86 x 10 9n cm-2 s-I (1 MW reactorpower) using a 10.2-cm-thick
collimator with a 20-mm diameter aperture. The collimator was
constructed from a 1:1 mixture oflithium fluoride and epoxy resin.
The physical dose rates (Gy MW-1 min) were: 0.02 (per jg '0B g-')
for the '0B(n, a)7Li reaction; 0.11 for the fast neutron interaction
with hydrogen 'H(n,n)p; 0.05 for the nitrogen neutron capture
reaction ('4N(n,p)14C); and 0.14 for the total gamma-ray compo-
nent (beam and induced in tissue by the 'H(n,y)2H reaction).
Irradiations
The 20-mm-diameter irradiation field was delimited at its lower
margin by the large dorsal spine of vertebra T2. The thickness of
tissue between the skin surface and the centre ofthe spinal cord, in
this region of the body, was 10.0 ± 1.0 mm. This was assessed
directly in cross-sectioned rats and also from radiographs.
An ip injection of ketamine (120 mg kg-') and xylazine
(20 mg kg-') was used to maintain anaesthesia during the irradia-
tions. The anaesthetized rat was supported in a body radiation
shield (Joel et al, 1990; Morris et al, 1994b) that ensured that the
rat was securely supported during irradiation and that the irradia-
tion field was maintained perpendicular to the thermal neutron
beam, with the dorsal surface ofthe neck abutting the collimator.
A 0.5-ml blood sample was taken immediately before thermal
neutron irradiation, and the boron content determined using
prompt gamma spectrometry. On average, seven rats were irradi-
ated per dose group. The various dose groups are detailed in Table
1. Irradiation commenced 1 h after BPA administration. Rats that
developed limb paralysis (myelopathy) were perfusion fixed under
ketamine-xylazine anaesthesia with a mixture of 10% formal
saline with 1% acetic acid. The spinal cord was removed for
histopathological analysis.
Dose-effect curves for the incidence of limb paralysis were
fitted using probit analysis. The doses required to produce a 50%
incidence of paralysis (ED50) were calculated from these curves.
Errors indicate the standard error ofthe mean (+ s.e.).
Boron biodistribution
Boron levels in blood, spinal cord and brain were measured over
a 3-h time period after the i.p. injection of BPA, using prompt
gamma or inductively coupled atomic emission spectrometry. The
BPA-fructose solution contained either 50 mg of BPA ml-1
injected in a volume of4 ml (samples were taken at 2 and 3 h), or
85 mg BPA ml-' injected in volumes of 3.5 or 5.0 ml (samples
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Figure 2 Dose-related changes in the incidence of rats developing
myelopathy within 30 weeks. Blood '°B concentrations at the time of thermal
neutron irradiation were approximately 19 9g g-' (data from Coderre et al,
1995) *; approximately 42g.g g-1 A; and approximately 93gg g-1 .
30- Laboratory (Coderre et al, 1997), and the irradiation geometry of a
representative BNCTpatient with a tumourextending to a depth of
5.2 cm in the brain, was used to simulate radiation doses delivered
20 to tumour and surrounding normal brain tissue. '°B concentrations
- - - - - in the blood and tumour were entered into the treatment planning
l0
- .....-..... .. programme, together with appropriate RBE and compound biolog-
ical effectiveness (CBE) factor values. Treatment plans using
0- I Idifferent imput parameters were prepared. The plans were
1.0 1.5 2.0 2.5 3.0 designed so that the peak dose to a 1-cm3 volume ofnormal brain,
Time after injection (h) at the maximum thermal neutron fluence, delivered in a single
C fraction using a single irradiation field, was 12.6 Gy-Eq (physical
C0 dose converted to the photon equivalent dose using the appropriate
i _ RBE and CBE factors).
0-
0-O
RESULTS
Boron biodistribution
Three doses of BPA, 700, 1000 and 1600 mg kg-', were used to
0- evaluate the biodistribution of '°B in blood, spinal cord and brain
afterip injection. At the lowest dose ofBPA used, blood '°B levels
remained relatively stable over the 3 h sampling period (Figure
0 o - t _ _ _ = ......... - - -^~ l-~h*~.................. 1A). At higher doses of BPA, blood "'B concentrations were
greatest at 1 h after BPA administration, and thereafter exhibited a
°. , biphasic clearance profile (Figure lB and C). The largest decline
1.0 1.5 2.0 2.5 3.0 in '°B levels occurred between 1 and 2 h after injection and was
Time after injection (h) most pronounced (approximately 45%) at the highest '°B concen-
Time-related changes in blood, brain and spinal cord 10Boron tration. In contrast to theblood, levels of '°B in CNS tissue did not
fterthe intraperitoneal injection of BPA at doses of A, 700 mg kg-'; decline with time after the administration of BPA (Figure 1).
ng kg-'; and C, 1600 mg kg-'. Blood A; brain *; spinal cord *. Considered overall, there was a slow but progressive increase in
not shown are contained within the symbol the 'B content of both the spinal cord and the brain with time.
Levels of '°B tended to be higher in the brain than in the spinal
cord, although the differences were relatively minor compared
en at 1, 2 and 3 h). Three rats were used at each time point, with the blood. At the time of irradiation (1 h after ip injection of
ting a total of27 animals. BPA), the "'B concentration ratio for the blood relative to the
spinal cord increased from approximately 5:1 to approximately
ted patient treatment planning 10:1 in the 1000 and 1600 mgkg-' BPA dose groups respectively.
In a previous study (Coderre et al, 1995), rats ofan identical strain,
;reatment planning software (Nigg et al, 1997), which is age and sex were irradiated with thermal neutrons at 3 h after the
y being used in clinical studies at Brookhaven National administration of 700 mg kg-' BPA. Data from the present study
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Table 2 ED50, RBE and CBE factors (±s.e.) for myelopathy after irradiation with X-rays or thermal neutrons - alone or in combination with BPA. Blood '°B
concentration (ig g-1) is given in parenthesis
Radiation Thermal beam dose component (Gy) 10B(n, a)7Li dose component (Gy) Total dose (Gy)
Beam+BPA (93) 3.4 ± 0.7 21.6 ± 0.5 25.0 ± 0.6
Beam+BPA (42) 4.6 ± 0.9 12.9 ± 0.6 17.5 ± 0.7
Beam+BPA (19)a 7.0 ± 0.5 6.8 ± 0.2 13.8 ± 0.6
Beam+BPA (12)b 8.9 ± 0.4 4.9 ± 0.7 13.8 ± 0.5
Beam-onlyb 13.6± 0.4
X-raysc 19.0± 0.2
aData from Coderre et al (1995); bdata from Morris et al (1994a); cdata from Wong et al (1993).
Table 3 RBE and CBE factors (±s.e.) for myelopathy after irradiation with thermal neutrons - alone or in combination with BPA. CBE factors, corrected to take
into account changes in the RBE of the thermal neutron beam with dose, are included. Blood '°B concentration (ig g-1) is given in parenthesis
Irradiation modality RBE of thermal beam component aCBE factor RBE adjusted
of the total radiation dose CBE factor
Beam + BPA (93) 2.57± 0.11 0.66 ± 0.07 0.48 ± 0.18
Beam + BPA (42) 2.25 ± 0.07 0.97 ± 0.11 0.67 ± 0.23
Beam + BPA (19)b 1.86 ± 0.04 1.34 ± 0.13 0.88 ± 0.14
Beam + BPA (12)c 1.67 ± 0.03 1.33 ± 0.16 0.85± 0.17
Beam only 1.40 ± 0.04
aThermal beam RBE of 1.40 used in all calculations; bdata from Coderre et al (1995); cdata from Morris et al (1994a).
indicated that the '°B concentration ratio for the blood relative to
the spinal cord would have been approximately 3:1 at the time of
irradiation. Similar ratios were also obtained for the two higher
dose groups at 3 h after BPA administration.
Dosimetry
The physical absorbed radiation dose from the '0B(n,a)7Li neutron
capture reaction was calculated using the mean '0B concentrations
in the blood, measured at the time of irradiation. Variation in the
'0B concentrations resulted in a corresponding variation in the
calculated doses from the '0B(n,aX)7Li reaction. This produced a
potential variation in the total dose (thermal beam plus '0B(n,a)7Li
dose) of< 2.1%.
Irradiation times were short (4.0-8.2 min), due to the fact that
the BMRR reactor was operated at full power (3 MW). As aresult,
fluctuations in the '°B content ofthe blood were minimal over the
period ofirradiation.
Response to boron neutron capture irradiation
The latent intervals before the onset of limb paralysis were
20.0 ± 0.6 and 20.0 ± 1.2 weeks after irradiation with thermal
neutrons in combination with BPA at blood '°B concentrations of
approximately 42 and approximately 93 ,ug/g respectively. No rats
were lost from other causes during the follow up period of 32
weeks after irradiation. The radiation-induced lesions in the spinal
cord were characterized by white matter necrosis.
The dose-related incidences of rats developing limb paralysis
are shown in Figure 2. The doses required to produce a 50% inci-
dence ofparalysis, the ED 5 values, were calculated from the dose
effect curves. The ED 5 values, expressed in terms ofthe physical
doses from the thermal beam and '0B(n,a)7Li components and the
total physical dose are given in Table 2.
Comparison with previously published dose-response data for
the spinal cord, using rats ofan identical strain, age and sex (Morris
et al, 1994a; Coderre et al, 1995), indicated that the ED50 (total
dose) for limb paralysis was comparable at blood '°B concentra-
tions of 12.0 ± 0.5 and 18.7 ± 0.6 ,ug g-'. However, further increase
in blood '°B levels resulted in higher ED50 values for paralysis
(Table 2). In the dose group of rats with the greatest blood '°B
concentration (approximately 93 jg g-') the thermal beam compo-
nent of the total physical dose was only approximately 14%. This
increased to approximately 65% of the total physical dose in the
group with the lowest (approximately 12 jig g-') blood '°B concen-
tration at the time ofirradiation. The gamma component ofthe total
physical dose decreased with increasing blood '°B concentration
from approximately 30% (approximately 12jg g-') to approxi-
mately 6% (approximately 93 jig g-'). In contrast, the '0B(n,a)7Li
reaction component of the total physical dose increased from
approximately 36% in the group ofrats with the lowest '°B concen-
tration in the blood to approximately 86% in the dose group ofrats
with the highest blood '°B concentration. The other high LET
components (fast neutrons and induced protons) of the total dose
decreased from approximately 34 to approximately 7% as blood
'°B levels were increased from approximately 12jg g' to approxi-
mately 93 jg g-'.
In defining the biological effects of the '0B(n,a)7Li neutron
capture reaction relative to photons, the term CBE factor was used
as an alternative to relative biological effectiveness (RBE). The
rational behind this has been discussed in detail previously (Morris
et al, 1994a,b). Calculation of the CBE factor is similar to that of
the relative biological effectiveness (RBE) namely:
CBE factor = (X-ray ED50) - (thermal beam component of
ED50x RBE)/'0B(n,a)7Li component ofED50
It is well established that for high LET radiations, the RBE
increases as the dose decreases (Hall, 1988). Changes in the RBE
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Table 4 Simulated radiation doses to the brain and tumour of a representative BNCT patient using a range of blood 10Boron concentrations. The CBE factor
values used were obtained from the rat spinal cord studies
Blood 10B content (rg g-1) CBE factor value Peak brain dose (Gy-Eq) Average brain Average tumour Minimum tumour
dose (Gy-Eq) dose (Gy-Eq)a dose (Gy-Eq)a
90 1.34 12.6 1.3 82.1 43.0
40 1.34 12.6 1.5 69.6 36.8
12 1.34 12.6 1.8 44.6 24.9
aCBE factor value of 3.8 was used for tumour (Coderre et al, 1993); RBE value of 3.2 was used for the 14N(n,p)'4C and 'H(n,n')p reactions in tumour and normal
tissue.
of the BMRR thermal neutron beam with dose have been calcu-
lated previously (Morris et al, 1997), and are described by the
equation e (-0.4499xLn[dose] +1.4945). This equation was used to calculate
the thermal neutron beam RBE at the various dose levels specified
in Table 2. RBE and CBE factor values, adjusted to take into
account the change in RBE with dose, are listed in Table 3. Also
included in Table 3, by way of comparison, are the CBE factors
calculated without adjustment for the change in RBE of the
thermal beam with dose.
The RBE ofthe beam at the ED5 level ofeffect (13.6 ± 0.4 Gy)
is relatively low at 1.40 ± 0.04 (Morris et al, 1994a). However, it
increases progressively as the thermal beam dose component of
the total dose decreases (Table 3). It is evident that the CBE factors
for BPA, calculated using a single RBE value of 1.40 for the
thermal beam, are higher than those obtained after adjustment for
the change in beam RBE with dose (Table 3). For example the
CBE factor estimated for BPA at a blood concentration of approx-
imately 19 jig g-' was 1.34 ± 0.13, compared with 0.88 + 0.14,
after correction for the increase in the RBE of the thermal beam
[i.e. the RBE ofthe thermal beam was 1.40 at 13.6 Gy (beam-only
ED50) compared with 1.86 at 7.0 Gy (beam component ofED50)].
At the two lower blood '°B concentrations used in previous
studies (Morris et al, 1994a; Coderre et al, 1995), similar CBE
factors were obtained for BPA (Table 3). However, at the higher
blood '°B levels used in the present study, the calculated CBE
factors for BPA were significantly lower (P < 0.05, Student t-test)
than those obtained previously. These findings indicate a link
between blood:CNSI'B concentration ratios at the time of irradia-
tion and the CBE factor, such that the CBE decreases as the
concentration ratio increases (at values > 3:1).
Simulated patient treatment planning
The peak brain dose, defined as the maximum radiation dose deliv-
ered to the normal brain adjacent to the tumour (at a depth of 2.5-
3 cm below the surface of the skull), was 12.6 Gy in all of the
simulations (Table 4). The average dose delivered to the total
volume of the normal brain was approximately 1.5 Gy. This was
because of the rapid fall in the intensity ofthe epithermal neutron
beam at depths of . 3 cm in the brain, using an 8-cm-diameter
collimator. A range of blood '0B levels were used to assess the
effects of progressively increasing the BPA dosage. A number of
assumptions were made in these calculations, namely that the
biodistribution of '°B in the blood relative to the CNS was similar
in rats and in man, and that the tumour to blood '0B concentration
ratio was 3:1. The CBE factor used for BPA in dose calculations
related to the tumour was 3.8 (Coderre et al, 1993). Increasing the
'°B level in the blood had the effect of progressively boosting the
radiation dose delivered to the tumour. For example, the minimum
tumour dose was increased by a factor of approximately 1.7 in
increasing the blood concentration from 12 jg g-' to 40 jg g-'
(Table 4). The minimum tumour dose is the radiation dose deliv-
ered to the tumour at its maximum depth in the brain. The fall-offin
the intensity of the epithermal neutron beam with increasing depth
in the tumour, accounts for the progressive decrease in the total
radiation dose (beam plus '0B(n,a)7Li neutron capture reaction).
DISCUSSION
The biodistribution data obtained in the present study indicated
that the ratio of '0B in the blood relative to CNS tissue changed
with time after the administration of BPA. Considered overall, the
concentration of '°B in the CNS parenchyma increased progres-
sively with time over the 3 h observation period, but was relatively
low at all dose levels. Similar observations were made in a
previous study (Coderre et al, 1994), in which BPA was adminis-
tered to an identical strain of rat at a dose of 1200 mg kg-'. In this
study, '°B levels (approximately 18 jg g-') in the brain plateaued
at 3 to 6 h after BPA administration, and thereafter declined
slowly, reaching a level ofapproximately 5 jig g- after 24 h.
Late radiation damage to CNS tissue, induced by thermal
neutrons in the presence of high levels of '°B in the blood, is
caused primarily by radiation effects from the high LET 7Li and a
particles produced by the '0B(n,C)7Li neutron capture reaction on
the endothelial cells lining the walls ofblood vessels (Morris et al,
1994c; 1996b). These cells are the primary radiation target in the
blood vessel (Calvo et al, 1988), damage to which is responsible
for the late radiation effects seen in the CNS after BNC irradiation.
The magnitude of the radiation dose from the '0B(n,a)7Li reaction
that reaches the nuclei ofvascularendothelial cells is dependent on
the distribution ofa given boron delivery agent. Forexample, with
borocaptate sodium (BSH), which does not cross the blood-brain
barrier and distribute in the CNS parenchyma, damage to the blood
vessel endothelial cells comes primarily from the high LET parti-
cles produced by neutron capture reactions occurring in the blood.
The parenchymal tissue elements of the CNS receive a relatively
small dose of radiation because of the limited range (< 9 jim) of
these particles. Theoretical calculations (Kitao, 1975; Rydin et al,
1976) indicate that the endothelial cell nucleus receives one-third
to one-fifth ofthe '0B(n,a)7Li dose to the blood, depending on the
average diameter of the vessels (< 8 jm). It is assumed in these
calculations that the '°B content of the endothelial cell is negli-
gible. Thus, only a small proportion ofthe radiation dose, derived
from thermal neutron activation of '0B in the blood, is actually
delivered to the endothelial cell nucleus. In the case of BSH, the
attenuation of the '0B(n,C)7Li dose in the blood vessel lumen, and
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the predominant exclusion ofBSH from the CNS parenchyma, are
the major factors resulting in the low CBE factor. This has been
estimated to be approximately 0.35 over a wide range ofblood '°B
concentrations (Morris et al, 1996a).
In contrast to BSH, BPA penetrates the blood-brain barrier and
distributes in the CNS parenchyma (Coderre et al, 1992). As a
result of this, there is a contribution to the total radiation dose
received by the endothelial cell from '0B(n,a)7Li neutron capture in
the surrounding CNS parenchyma. When BPA concentrations are
similar in the blood and CNS parenchyma, it has been estimated
that one-third ofthe total '°B(n, aX)7Li dose delivered to the vascular
endothelial cell nucleus comes from the blood and two-thirds from
the CNS parenchyma (Rydin et al, 1976; Coderre et al, 1992). This
estimate is in agreement with the findings from the spinal cord
studies, which indicate that, for low levels of '°B (< 20 jg g1) in
the blood, the CBE factor for BPA is approximately 3 times higher
for BPA than for BSH (Morris et al, 1994a; 1996a).
The RBE of the thermal beam component of the total radiation
dose must be taken into consideration in the calculation of the
CBE factor. Studies with the BMRR thermal beam, using the rat
spinal cord model, indicated an RBE value of 1.4, for the 'full
effect' (Morris et al, 1994a). This RBE value is frequently used to
represent the biological effectiveness of the 'partial effect' of the
thermal beam component of BNC irradiation modalities.
However, it has been established that the RBE ofhigh LET radia-
tion, such as fast neutrons, increases as the dose decreases,
compared with 250-kV X-rays, for the same partial effect (Hall,
1988). This phenomenon has also been documented for thermal
neutron beams (Coderre et al, 1995; Morris et al, 1997) using a rat
spinal cord model. CBE factors for BPA (approximately 19 jig g-'
'0B in blood) and BSH have recently been recalculated to take into
account the changing RBE ofthe thermal neutron beam with dose
(Morris et al, 1997). In all cases, the recalculated CBE factors
(including those ofthe present study) were lower than those previ-
ously published (Morris et al, 1994a; 1996a; Coderre et al, 1995).
However, from a clinical perspective, it is inadvisable to use the
revised CBE factor values in dose (Gy-Eq) calculations. This is
because at the present time there are no accurately determined
values for RBEs ofepithermal neutron beams that show how they
might vary with dose.
The dose contribution from the '0B(n,a)7Li reaction is routinely
measured on the basis of the blood '°B concentration during the
course ofirradiation. No account is taken of the '0B content ofthe
CNS parenchyma in the dose calculations. This is because it is not
possible to obtain CNS tissue samples for '0B analysis during the
course ofBNC irradiation. The physical dose delivered to the CNS
is therefore described in terms ofthe physical dose delivered to the
blood, and the CBE factor is calculated on the basis of this dose.
The CBE factors that have been measured experimentally reflect
the different biodistributions of the boron delivery agents and the
attenuation of the radiation dose due to the geometry of the blood
vessel wall. In the case ofBSH, using myeloparesis in the rat as the
end-point, the CBE factor was calculated at approximately 0.36
(Morris et al, 1996a). The value for BPA was approximately 0.88
at a similar blood '°B level of approximately 20jg g-' (Morris et
al, 1997). In the derivation ofCBE factors for potential use in clin-
ical protocols, it is advisable to use a wide range of blood '°B
concentrations. Studies carried out with BSH at blood '°B levels in
the range 20-120 jg g-' (Morris et al, 1996a), indicated that the
CBE factor remained constant. However, progressive escalation of
the dose of BPA to give blood '°B concentrations in the range
12-90 jg g-' (Morris et al, 1994a; 1997; present study) resulted in
CBE factors that varied from 0.88 to 0.48. In contrast to BSH,
major differences were found in the relative distribution of '°B in
the blood and CNS parenchyma after the administration of BPA
at different dose levels. At the highest concentration of '°B in
the blood (approximately 90 jg g-1), levels of '°B in the CNS
parenchyma were relatively low, whereas at the lowest concentra-
tion of '°B in the blood (19 jig g') levels of '°B in the CNS
parenchyma were relatively high at the time of irradiation. These
major changes in the biodistribution of '°B are the most probable
cause of the variations in the calculated CBE factor. At low levels
of '°B in the blood, the extra luminal dose from the '0B(n,a)7Li
reaction is relatively high, whereas at high levels of '°B in the
blood it is relatively low. Because the extraluminal dose from the
'0B(n,a)7Li reaction is not included in the CBE factor calculations,
the CBE factor appears to be higher at low '°B blood concentra-
tions than at high '0B blood concentrations. It should be noted
when comparing the two lowest blood '°B concentration groups
(12 and 19 jg g-1) that the calculated CBE factors were similar.
This was in spite of the fact that the blood:CNS '0B concentration
ratios differed by a factor of approximately 2. However, at these
relatively low blood '0B levels the overall '0B(n,a)7 Li dose (intra-
and extraluminal components), expressed as a percentage of the
total physical dose delivered to the blood vessel endothelial cell,
are similar (approximately 50%).
Owing to the fact that the rate of accumulation/clearance of '°B
(BPA) from the CNS parenchyma is relatively slow, variation in
'°B concentration over the time course of irradiation is negligible.
This is true in both experimental and clinical studies (Coderre et
al, 1996), using BPA as the neutron capture agent. The most salient
consideration in translating experimentally derived CBE factors
for BPA to the clinical situation is similarity in the '°B distribution
in the CNS of the animal model and man. At the low dose of BPA
(250 mg kg-') currently in use in the BNL clinical trial, '0B distrib-
ution in the human brain is similar to that in the rat or dog at low
blood '°B concentrations (Coderre et al, 1992 and unpublished
results; Morris et al, 1994a).
Supra-additive interactions between photons and fast neutrons
or a-particles in a mixed irradiation field have been demonstrated
in vitro (Murthy et al, 1975; Railton et al, 1975; McNally et al,
1984; 1988). The combined biological effect oftwo different types
of radiation is considered to be supra-additive if it is greater than
the two radiations acting independently. In a previous study on the
rat spinal cord, using BSH as the neutron capture agent (Morris et
al, 1996a), the ratio of low LET radiation (gamma rays) to high
LET radiation (fast neutrons, a-particles, 7Li particles and induced
protons) varied from approximately 1:5 to approximately 1:19 as
the blood '°B concentration was increased from approximately
20 jg g-' to approximately 120 jg g-'. No evidence of a super-
additive effect was found. This finding would tend to preclude
super-additivity as a contributory factor in the variation in the
value of the CBE factor for BPA found in the present study.
The present findings have obvious clinical implications. The
current treatment protocol in the Brookhaven BNCT clinical
studies involves a BPA dose of 250 mg kg' body weight. This
delivers blood '0B concentrations of 10-15 jg g' at the time of
treatment. Simulation of the radiation doses delivered to the
tumour of a typical glioma patient involved in the Brookhaven
study, indicates a distinct advantage in moving to considerably
higher blood '0B levels than those currently used. For example, at a
blood '°B concentration of 40 jg g', the minimum tumour dose
British Journal of Cancer(1997) 76(12), 1623-1629 0 CancerResearch Campaign 1997CNS tolerance to BNCT 1629
(i.e. the radiation dose delivered to the tumour at its maximum
depth in the brain) can be increased by approximately 50%. A CBE
factor of 1.3 was used in the dose calculations. Given the fact that
in the current BNL clinical protocol BPA administration involves a
2-h infusion followed by a 45-min gap before the commencement
ofirradiation, it is unlikely that the CBE factor forthe normal CNS
will be lower than 1.3 (i.e. the blood:CNS '°B concentration ratio is
unlikely to exceed 3:1). The experimental data from rat CNS
studies suggests that 3 h after the administration ofBPA the blood:
CNS '°B concentration ratio is unlikely to exceed 3:1, even after
high doses of BPA. However, the possibility exists that this ratio
could vary in future BPA administration protocols designed to
maximize tumour uptake of '0B. The findings of the present study
suggest that such variations are unlikely to result in an increase in
the CBE factor for BPA, and could result in lower CBE factors at
blood:CNS '0B concentration ratios in excess of3:1.
The microdistribution of '0B in rats given BPA has recently been
analysed in two brain tumour models using ion microscopy (Smith
et al, 1996). It was noted that the '°B content of local metastatic
cells was about half that of viable cells in the adjacent primary
tumour. This finding, taken together with the results ofthe present
study, strongly supports the use of considerably higher doses of
BPA in future BNCT clinical protocols to optimize the radiation
dose to any local metastatic spread.
CONCLUSIONS
The biodistribution profile of BPA in the normal CNS of the rat
changed as levels of '0B increased in the blood. The blood:CNS
'°B concentration ratio decreased progressively with time after
BPA administration. It is this ratio, rather than absolute blood '0B
levels, that determines the magnitude of the CBE factor. The
higher the ratio the lower the CBE factor. Data from the present
study indicate that, using the current BNCT clinical administration
protocol for BPA, the CBE factor is unlikely to increase when
higher BPA doses are used. Computer simulations using the BNL
clinical treatment planning software indicate that a significant
boost in the radiation dose delivered to the tumour at depth in the
brain can be achieved by using higher BPA dosages than those in
current clinical use.
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